Organisation paid for research Program year 2025 Source: CMS Open Payments

Spokane Urology PS

Neither a doctor nor a teaching hospital

Research payments

$640,753

531 payments

Through program year 2025, Spokane Urology PS is reported as receiving $640,753 in research payments, across 531 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$102,759	97
2024	Research	$135,760	96
2023	Research	$374,511	324
2022	Research	$27,724	14

Breakdown

Who paid Research payments · program years 2022–2025

Bayer HealthCare Pharmaceuticals Inc. $491,805 464 payments
Sumitomo Pharma America, Inc. $113,437 58 payments
Dendreon Pharmaceuticals LLC $35,511 9 payments

Studies the money was for Research payments · program years 2022–2025

Open-label external control arm study of darolutamide plus A $337,672 312 payments
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC $102,212 93 payments
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned $51,921 59 payments
A Multi-Center, Prospective, Observational Study of Patients Being Treated With Orgovyx $42,420 12 payments
A Multi-Center, Prospective, Observational Study of Patients Being Treated With Orgovyx $36,063 24 payments
ProvONE Study $35,108 8 payments
Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (Replace-Cv) $22,143 14 payments
Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (Replace-Cv) $12,812 8 payments
ProvONE $404 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.